PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2020-06-15

Date Title Company
15-Jun-2020 Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca(TM) (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer Jazz Pharmaceuticals plc
15-Jun-2020 Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine U.S. Food and Drug Administration
15-Jun-2020 Increasing global prevalence of infectious diseases Diagnosis markets and markets
15-Jun-2020 Growing importance of chromatography tests in the drug approval process markets and markets
15-Jun-2020 ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan ABIVAX
15-Jun-2020 Pharmacy Technician Certification Board (PTCB) Welcomes Al Carter and Scott Knoer to its Board of Governors Pharmacy Technician Certification Board (PTCB)
15-Jun-2020 New VENCLYXTO®▼(venetoclax) Data Demonstrate Utility Across Acute Myeloid Leukaemia (AML) Patients and Chronic Lymphocytic Leukaemia (CLL) AbbVie
15-Jun-2020 Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML Cardiff Oncology, Inc.
15-Jun-2020 New Phase 3 Data from LEO Pharma’s Dermatology Portfolio LEO Pharma
15-Jun-2020 SOTIO to Present New Preclinical Data on IL-15 Superagonist, SO-C101, at the 2020 AACR Virtual Annual Meeting II B3C newswire
15-Jun-2020 Original-Research: HAEMATO AG (von First Berlin Equity Research GmbH) HAEMATO AG
15-Jun-2020 (Covid-19) Impact Analysis : Surgical Hemostats Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2026 Qurate Business Intelligence
15-Jun-2020 Therapeutic Solutions International Issues "NOT US" Notice to Shareholders Therapeutics Solutions International, Inc.
15-Jun-2020 Therapeutic Solutions International Issues "NOT US" Notice to Shareholders Therapeutics Solutions International, Inc.
15-Jun-2020 New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis Janssen
15-Jun-2020 Marc Princen appointed new Global CEO for Mundipharma Mundipharma
15-Jun-2020 AI & Medicine — An Expert in AI-aided Drug Discovery and Medical Applications AI & Medicine
15-Jun-2020 Alfa Chemistry Testing Lab Offers an Exclusive Section for Regulatory Resources Alfa Chemistry Testing Lab
15-Jun-2020 Nanoform Finland Plc Appoints Peter Hänninen as General Counsel Nanoform
15-Jun-2020 Nanoform Finland Plc Appoints Peter Hänninen as General Counsel Nanoform